Personalized Medicine Breakthrough: Researchers Develop New Method for Gastric Cancer Treatment

Strategic Insights -

Researchers from the University of Leipzig have made a groundbreaking discovery in the field of personalized medicine, developing a new method to assess individualized susceptibility to chemotherapy and immune checkpoint inhibitors in gastric cancer patients. By using pretherapeutic endoscopic tissue cultures (ePDTCs), the team has demonstrated the feasibility of this approach, showing that it can effectively assess tissue susceptibility to drugs. This research has the potential to revolutionize the treatment of gastric cancer, allowing for more targeted and effective therapies.

Key Takeaways:

  • The study used ePDTCs to assess individualized susceptibility to chemotherapy and immune checkpoint inhibitors in gastric cancer patients.
  • The team treated ePDTCs with various drugs, including 5-FU, FLOT regimen, SN38, and nivolumab, and observed dose-dependent responses and individualized susceptibility.
  • The research demonstrated that ePDTCs can be used to assess tissue susceptibility to drugs, warranting further investigation in larger cohorts to validate this model's potential alongside clinical treatments.
  • Financial support for this research came from HMU Health and Medical University Potsdam GmbH (9920).
  • The study highlights the importance of preserving tumor architecture to address the intricate interactions between stromal cells and tumor cell populations within a patient.
  • The research concluded that ePDTCs can effectively assess tissue susceptibility to drugs, but further investigation is needed to validate this model's potential alongside clinical treatments.

Statistics:

  • 2% autologous human serum was added to the culture media to enhance the adaptation of tumor tissue.
  • Dose-dependent responses were observed with SN38 across all samples (100% of samples).
  • Individual susceptibility to chemotherapy and immune checkpoint inhibitors was observed at low concentrations (1-10 mu M).
  • The study was conducted in a controlled environment, with all samples and treatments prepared under strict guidelines.

Sources:

  • NewsRx. New Findings on Personalized Medicine Described by Investigators at University of Leipzig (Personalized Drug Stratification Using Endoscopic Samples To Assess Ex Vivo Gastric Cancer Tissue Susceptibility To Chemotherapy and Immune Checkpoint Inhibitors). Health & Medicine Week. July 4, 2025; p 2729.
  • Personalized Drug Stratification Using Endoscopic Samples To Assess Ex Vivo Gastric Cancer Tissue Susceptibility To Chemotherapy and Immune Checkpoint Inhibitors. Clinical and Experimental Medicine, 2025;25(1).
  • Springer-verlag Italia Srl. Clinical and Experimental Medicine. Springer - www.springer.com; Clinical and Experimental Medicine - www.springerlink.com/content/1591-8890/.